



**LISTING OF CLAIMS**

1. (Currently amended) An isolated molecule ~~comprising an antibody variable region~~ selected from the group consisting of: an intact antibody, a single chain variable region (ScFv), a monoclonal antibody, Fab, Fab', and Fab'2, which wherein said molecule specifically binds to an extracellular domain of TEM 17 as shown in SEQ ID NO: 230.
2. (Previously presented) The isolated molecule of claim 1 which is an intact antibody molecule.
3. (Original) The isolated molecule of claim 1 which is a single chain variable region (ScFv).
4. (Original) The isolated molecule of claim 1 which is a monoclonal antibody.
5. (Original) The isolated molecule of claim 1 which is a humanized antibody.
6. (Original) The isolated molecule of claim 1 which is a human antibody.
7. (Original) The isolated molecule of claim 1 which is bound to a cytotoxic moiety.
8. (Original) The isolated molecule of claim 1 which is bound to a therapeutic moiety.
9. (Original) The isolated molecule of claim 1 which is bound to a detectable moiety.
10. (Original) The isolated molecule of claim 1 which is bound to an anti-tumor agent.
- 11-17. (Cancelled)

18. (Previously presented) The isolated molecule of claim 4 which is bound to a cytotoxic moiety.
19. (Previously presented) The isolated molecule of claim 4 which is bound to a therapeutic moiety.
20. (Previously presented) The isolated molecule of claim 4 which is bound to a detectable moiety.
21. (Previously presented) The isolated molecule of claim 4 which is bound to an anti-tumor agent.
22. (Previously presented) The isolated molecule of claim 6 which is bound to a cytotoxic moiety.
23. (Previously presented) The isolated molecule of claim 6 which is bound to a therapeutic moiety.
24. (Previously presented) The isolated molecule of claim 6 which is bound to a detectable moiety.
25. (Previously presented) The isolated molecule of claim 6 which is bound to an anti-tumor agent.
26. (Currently amended) The isolated molecule of claim 1 ~~wherein the antibody variable region~~ which specifically binds to residues 137-244 or 280-344 of TEM17.
27. (Currently amended) The isolated molecule of claim 2 ~~wherein the antibody variable region~~ which specifically binds to residues 137-244 or 280-344 of TEM17.
28. (Currently amended) The isolated molecule of claim 3 ~~wherein the antibody variable region~~ which specifically binds to residues 137-244 or 280-344 of TEM17.

29. (Currently amended) The isolated molecule of claim 4 ~~wherein the antibody variable region~~ which specifically binds to residues 137-244 or 280-344 of TEM17.
30. (Currently amended) The isolated molecule of claim 5 ~~wherein the antibody variable region~~ which specifically binds to residues 137-244 or 280-344 of TEM17.
31. (Currently amended) The isolated molecule of claim 6 ~~wherein the antibody variable region~~ which specifically binds to residues 137-244 or 280-344 of TEM17.
32. (Currently amended) The isolated molecule of claim 1 ~~wherein the antibody variable region~~ which specifically binds to residues ~~18-427~~ 19-426 of TEM17.
33. (Currently amended) The isolated molecule of claim 2 ~~wherein the antibody variable region~~ which specifically binds to residues ~~18-427~~ 19-426 of TEM17.
34. (Currently amended) The isolated molecule of claim 3 ~~wherein the antibody variable region~~ which specifically binds to residues ~~18-427~~ 19-426 of TEM17.
35. (Currently amended) The isolated molecule of claim 4 ~~wherein the antibody variable region~~ which specifically binds to residues ~~18-427~~ 19-426 of TEM17.
36. (Currently amended) The isolated molecule of claim 5 ~~wherein the antibody variable region~~ which specifically binds to residues ~~18-427~~ 19-426 of TEM17.
37. (Currently amended) The isolated molecule of claim 6 ~~wherein the antibody variable region~~ which specifically binds to residues ~~18-427~~ 19-426 of TEM17.
38. (New) The isolated molecule of claim 1 wherein said molecule binds to TEM17 at least 2 times more than to irrelevant antigen or antigen mixture.
39. (New) The isolated molecule of claim 1 wherein said molecule binds to TEM17 at least 5 times more than to irrelevant antigen or antigen mixture.